Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells $10,328.00 in Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 1,291 shares of the firm’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $8.00, for a total transaction of $10,328.00. Following the sale, the chief financial officer now directly owns 98,156 shares of the company’s stock, valued at approximately $785,248. The trade was a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Phathom Pharmaceuticals Stock Performance

Shares of PHAT stock opened at $7.45 on Friday. The stock has a market capitalization of $509.41 million, a price-to-earnings ratio of -1.31 and a beta of 0.56. Phathom Pharmaceuticals, Inc. has a one year low of $6.07 and a one year high of $19.71. The company’s 50-day simple moving average is $12.11 and its 200-day simple moving average is $13.09.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PHAT. Bank of New York Mellon Corp raised its position in shares of Phathom Pharmaceuticals by 20.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 114,721 shares of the company’s stock valued at $1,182,000 after acquiring an additional 19,500 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Phathom Pharmaceuticals by 42.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company’s stock valued at $104,000 after purchasing an additional 2,987 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Phathom Pharmaceuticals by 17.1% during the second quarter. Rhumbline Advisers now owns 55,178 shares of the company’s stock worth $568,000 after purchasing an additional 8,075 shares during the period. Marshall Wace LLP acquired a new stake in shares of Phathom Pharmaceuticals during the second quarter worth $1,161,000. Finally, Oracle Investment Management Inc. bought a new position in shares of Phathom Pharmaceuticals in the 2nd quarter worth about $2,318,000. Institutional investors own 99.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on PHAT shares. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Wednesday, December 11th. HC Wainwright restated a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.